Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Pulmonary epithelial lining fluid concentrations after use of systemic amphotericin B lipid formulations.

Literature DB >> 19704134

Pulmonary epithelial lining fluid concentrations after use of systemic amphotericin B lipid formulations.

Stefan Weiler¹, Gerda Falkensammer, Angelika Hammerer-Lercher, Markus Anliker, Helene Vogelsinger, Michael Joannidis, Stefan Dunzendorfer, Markus Stein, Romuald Bellmann.

Abstract

Amphotericin B (AMB) concentrations were determined in pulmonary epithelial lining fluid (ELF) of 44 critically ill patients, who were receiving treatment with liposomal AMB (LAMB) (n = 11), AMB colloidal dispersion (ABCD) (n = 28), or AMB lipid complex (ABLC) (n = 5). Mean AMB levels (+/- standard errors of the means) in ELF amounted to 1.60 +/- 0.58, 0.38 +/- 0.07, and 1.29 +/- 0.71 microg/ml in LAMB-, ABCD-, and ABLC-treated patients, respectively (differences are not significant).

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2009 PMID： 19704134 PMCID： PMC2772304 DOI： 10.1128/AAC.00796-09

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

28 in total

1. Concentrations of single-dose meropenem (1 g iv) in bronchoalveolar lavage and epithelial lining fluid.

Authors: B Allegranzi; A Cazzadori; G Di Perri; S Bonora; M Berti; L Franchino; A Biglino; A Cipriani; E Concia
Journal: J Antimicrob Chemother Date: 2000-08 Impact factor: 5.790

2. Levofloxacin penetration into epithelial lining fluid as determined by population pharmacokinetic modeling and monte carlo simulation.

Authors: G L Drusano; S L Preston; M H Gotfried; L H Danziger; K A Rodvold
Journal: Antimicrob Agents Chemother Date: 2002-02 Impact factor: 5.191

3. Lipid formulations of amphotericin B for empirical treatment of fever and neutropenia.

Authors: Richard Frothingham
Journal: Clin Infect Dis Date: 2002-10-01 Impact factor: 9.079

Review 4. Lipid formulations of amphotericin B: recent progress and future directions.

Authors: J W Hiemenz; T J Walsh
Journal: Clin Infect Dis Date: 1996-05 Impact factor: 9.079

5. Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution.

Authors: S I Rennard; G Basset; D Lecossier; K M O'Donnell; P Pinkston; P G Martin; R G Crystal
Journal: J Appl Physiol (1985) Date: 1986-02

Review 6. Clinical role of bronchoalveolar lavage in adults with pulmonary disease.

Authors: R A Goldstein; P K Rohatgi; E H Bergofsky; E R Block; R P Daniele; D R Dantzker; G S Davis; G W Hunninghake; T E King; W J Metzger
Journal: Am Rev Respir Dis Date: 1990-08

7. Pharmacokinetics and lung concentrations of ertapenem in patients with ventilator-associated pneumonia.

Authors: Emmanuel Boselli; Dominique Breilh; Marie-Claude Saux; Jean-Baptiste Gordien; Bernard Allaouchiche
Journal: Intensive Care Med Date: 2006-10-13 Impact factor: 17.440

8. Determination of amphotericin B, liposomal amphotericin B, and amphotericin B colloidal dispersion in plasma by high-performance liquid chromatography.

Authors: P Egger; R Bellmann; C J Wiedermann
Journal: J Chromatogr B Biomed Sci Appl Date: 2001-09-05

9. Intrapulmonary pharmacokinetics and pharmacodynamics of itraconazole and 14-hydroxyitraconazole at steady state.

Authors: John E Conte; Jeffrey A Golden; Juliana Kipps; Marina McIver; Elisabeth Zurlinden
Journal: Antimicrob Agents Chemother Date: 2004-10 Impact factor: 5.191

10. Steady-state plasma and intrapulmonary concentrations of piperacillin/tazobactam 4 g/0.5 g administered to critically ill patients with severe nosocomial pneumonia.

Authors: Emmanuel Boselli; Dominique Breilh; Maxime Cannesson; Fabien Xuereb; Thomas Rimmelé; Dominique Chassard; Marie-Claude Saux; Bernard Allaouchiche
Journal: Intensive Care Med Date: 2004-04-01 Impact factor: 17.440

10 in total

1. Human tissue distribution of voriconazole.

Authors: Stefan Weiler; David Fiegl; Róisín MacFarland; Eva Stienecke; Rosa Bellmann-Weiler; Stefan Dunzendorfer; Michael Joannidis; Romuald Bellmann
Journal: Antimicrob Agents Chemother Date: 2010-11-15 Impact factor: 5.191

Review 2. Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.

Authors: Romuald Bellmann; Piotr Smuszkiewicz
Journal: Infection Date: 2017-07-12 Impact factor: 3.553

Review 3. Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antifungal, antitubercular and miscellaneous anti-infective agents.

Authors: Keith A Rodvold; Liz Yoo; Jomy M George
Journal: Clin Pharmacokinet Date: 2011-11-01 Impact factor: 6.447

4. Enhancing the Antibiofilm Activity of β-1,3-Glucanase-Functionalized Nanoparticles Loaded With Amphotericin B Against Candida albicans Biofilm.

Authors: Yulong Tan; Su Ma; Ting Ding; Roland Ludwig; Jintae Lee; Jiaman Xu
Journal: Front Microbiol Date: 2022-05-24 Impact factor: 6.064

Review 5. Administration and Dosing of Systemic Antifungal Agents in Pediatric Patients.

Authors: Kevin J Downes; Brian T Fisher; Nicole R Zane
Journal: Paediatr Drugs Date: 2020-04 Impact factor: 3.022

6. Pharmacokinetics of amphotericin B colloidal dispersion in critically ill patients with cholestatic liver disease.

Authors: Stefan Weiler; Elisabeth Überlacher; Julia Schöfmann; Eva Stienecke; Stefan Dunzendorfer; Michael Joannidis; Romuald Bellmann
Journal: Antimicrob Agents Chemother Date: 2012-07-30 Impact factor: 5.191

7. Population pharmacokinetics of conventional and intermittent dosing of liposomal amphotericin B in adults: a first critical step for rational design of innovative regimens.

Authors: William W Hope; Joanne Goodwin; Timothy W Felton; Michael Ellis; David A Stevens
Journal: Antimicrob Agents Chemother Date: 2012-08-06 Impact factor: 5.191